AVENUE THERAP. DL-,0001 (49Y.F)

3,1000 -0,0600 (-1,90%) A partir del 08:03AM CEST. Mercado abierto.

AVENUE THERAP. DL-,0001

1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
781 652 4500
https://www.avenuetx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 3

Descripción

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Gobierno corporativo

El ISS Governance QualityScore de AVENUE THERAP. DL-,0001, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.